The molecular mechanism of action of artemisinin--the debate continues.
O'Neill PM, Barton VE, Ward SA. · 2010
Read The molecular mechanism of action of artemisinin--the debate continues. by O'Neill PM, Barton VE, Ward SA. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6257357.txt.
Introduction
O'Neill, Barton, and Ward review the long debate over how artemisinin kills malaria parasites. Their review appeared in Molecules. Artemisinin comes from a plant used in Chinese medicine. Its drug family now leads malaria treatment worldwide. Combined forms are standard, to slow drug resistance. Warning signs of weaker response had appeared at the Thai-Cambodian border.
How the drug works inside the parasite is still unsettled. Several target molecules have been proposed over the years. The review weighs the proof for how the drug is switched on in the body. It also covers the main candidate targets. Artemisinin compounds also show effects against cancer cells and other parasites. Those wider uses make the mechanism question more pressing. Clear answers could guide safer, stronger follow up drugs.
Catalog record
| CREATOR | O'Neill PM, Barton VE, Ward SA. |
|---|---|
| YEAR | 2010 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
The Molecular Mechanism of Action of Artemisinin—The Debate Continues By Paul M. O’Neill, Victoria E. Barton, Stephen A. Ward Published in: Molecules DOI: 10.3390/molecules15031705 ABSTRACT Despite international efforts to ‘roll back malaria’ the 2008 World Malaria Report revealed the disease still affects approximately 3 billion people in 109 countries; 45 within the WHO African region. The latest report however does provide some ‘cautious optimism’; more than one third of malarious countries have documented greater than 50% reductions in malaria cases in 2008 compared to 2000. The goal of the Member States at the World Health Assembly and ‘Roll Back Malaria’ (RBM) partnership is to reduce the numbers of malaria cases and deaths recorded in 2000 by 50% or more by the end of 2010. Although malaria is preventable it is most prevalent in poorer countries where prevention is difficult and prophylaxis is generally not an option. The burden of disease has increased by the emergence of multi drug resistant (MDR) parasites which threatens the use of established and cost effective antimalarial agents. After a major change in treatment policies, artemisinins are now the frontline treatment to aid rapid clearance of parasitaemia and quick resolution of symptoms. Since artemisinin and its derivatives are eliminated rapidly, artemisinin combination therapies (ACT’s) are now recommended to delay resistance mechanisms. In spite of these precautionary measures reduced susceptibility of parasites to the artemisinin-based component of ACT’s has developed at the Thai-Cambodian border, a historical ‘hot spot’ for MDR parasite evolution and emergence. This development raises serious concerns for the future of the artemsinins and this is not helped by controversy related to the mode of action. Although a number of potential targets have been proposed the actual mechanism of action remains ambiguous. Interestingly, artemisinins have also shown potent and broad anticancer properties in cell lines and animal models and are becoming established as anti-schistosomal agents. In this review we will discuss the recent evidence explaining bioactivation and potential molecular targets in the chemotherapy of malaria and cancer. 1. INTRODUCTION Global warming has impacted upon malaria disease burden making it difficult to predict future disease patterns [1]. However the most critical problem facing the treatment of malaria is the development of resistance to classical quinoline antimalarial compounds such as chloroquine and antifols [2]. A significant discovery program by Chinese chemists in the 1970’s; ‘project 523’ has provided one of the most potent and effective antimalarials to date, artemisinin (1) [3]. Artemisinins are effective not only against multi-resistant strains of P. falciparum, but have broad stage specificity against the Plasmodium life cycle including activity throughout the asexual blood stages[4] and also the sexual gametocyte stages which may reduce the spread of the disease in areas of low transmission [5]. Representing a new class of antimalarial agents, artemisinin is a sesquiterpene trioxane lactone whose endoperoxide bridge is essential for antimalarial activity. Although the precise mechanism of action is still highly controversial [6]; the endoperoxide pharmacophore alone has stimulated the development of several different classes of totally synthetic endoperoxides including the trioxolane OZ277 (2) [7] and the tetraoxane 3 [8] (Figure 1). Understanding the mechanism of action of this class of drugs will allow the prediction of potential resistance mechanisms and aid targeted design of future antimalarial agents. Artemisinins have also been investigated for their antiproliferative effects against a wide range of cancer cell lines [9]. The promising in vitro profiles of several semi-synthetic analogues has prompted the call for more appropriate clinical studies to be performed [10,11]. In this review we will consider the different views regarding how artemisinin is first activated and its proposed molecular targets. The effect of artemisinin in cancer cells will also be considered with respect to similarities and differences to their action in malaria chemotherapy, factors which may be important in elucidating potential common mechanisms of action. 2. ACTIVATION OF ARTEMISININ 2.1. Bioactivation in parasites Within the malaria parasite host hemoglobin is degraded by a series of protease enzymes to release peptides and amino acids required for development and to create space within its digestive vacuole. During this process a build up of hematin occurs which is potentially toxic to the parasite (Figure 2). To circumvent this toxicity, the parasite has developed a mechanism whereby hematin undergoes biomineralization to form insoluble non-toxic hemozoin (malaria pigment). One of the first studies completed by the Meshnick group [14] suggested that the bioactivation of 1,2,4 trioxanes is triggered by iron (II) to generate toxic activated oxygen. The selectivity of artemisinin towards parasite-infected erythrocytes over normal erythrocytes was rationalised by the iron dependent bioactivation of the endoperoxide bridge. Since these initial findings two models of ring opening have been suggested that differ by their dependency on iron and involvement of carbon centred radicals. 2.1.1. Reductive scission model Early work by Posner [15,16,17] and Jefford [18,19] proposed that these oxygen centred radicals subsequently rearrange to form carbon centred radicals, although the nature of the proposed radical and the mechanistic pathways giving rise to their formation were different in each case. Low valent transition ions (ferrous heme or non heme exogenous Fe2+) were found to bind to artemisinin and after subsequent electron transfer induce reductive scission of the peroxide bridge to produce oxygen centred radicals which rearrange to give carbon centred radicals (Figure 3 A). Due to the unsymmetrical nature of the endoperoxide bridge, iron was found to interact with the peroxide in different ways to produce either a primary carbon centred radical or a secondary carbon centred radical. Both primary and secondary radicals, 4 and 5 [20,21] have been efficiently spin-trapped by electroparamagnetic resonance spin trapping techniques after being activated by iron [22]. 2.1.2. Open peroxide model The alternative model suggests that ring opening is driven by protonation of the peroxide or by complexation by Fe2+ (Figure 3 B). Haynes and co-workers have proposed that iron acts as a Lewis acid to facilitate ionic, rather than radical bioactivation of the artemisinins (which, it is proposed, are too short-lived to have any intermolecular interaction) [23]. In addition, it has also been suggested that non-peroxidic oxygen plays a role in facilitating ring opening of the peroxide to generate the open hydroperoxide [24,25,26]. The oxygen atom provides stabilization of the positive charge and, according to transition state theory, lowers the energy required for ring opening. Heterolytic cleavage of the endoperoxide bridge and subsequent capture of water leads to the formation of an unsaturated hydroperoxide 6, capable of irreversibly modifying protein residues by direct oxidation. Subsequent Fenton degradation of the hydroperoxide 6 produces a hydroxyl radical, a species that can subsequently oxidize target amino acid residues. To support this theory artemisinin has been shown to mediate N-oxidation of tertiary alkylamine derivatives via the intermediacy of such a ring opened peroxide form of artemisinin [25]. This alternative mechanism may have the potential to produce a whole host of reactive oxygen species that may have implications for the antimalarial activity of these compounds. 2.1.3. Iron-Dependent bioactivation vs. heme-dependent bioactivation in parasites The species originally thought responsible for bioactivation was heme iron, as this form of iron is in abundance within the parasite due to the degradation of hemoglobin releasing soluble heme. However, intracellular iron (II) and iron (III) occur also in equilibrium inside the